×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [49]
内容类型
期刊论文 [47]
会议论文 [2]
发表日期
2021 [4]
2020 [2]
2019 [7]
2018 [8]
2017 [4]
2016 [4]
更多...
学科主题
Biochemist... [1]
Cell Biolo... [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共49条,第1-10条
帮助
限定条件
专题:上海药物研究所
第一署名单位
第一作者单位
通讯作者单位
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Covalent sortase A inhibitor ML346 prevents Staphylococcus aureus infection of Galleria mellonella
期刊论文
RSC MEDICINAL CHEMISTRY, 2021, 页码: 12
作者:
Guan, Xiang-Na
;
Zhang, Tao
;
Yang, Teng
;
Dong, Ze
;
Yang, Song
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2021/12/16
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:
Meng, Jian
;
Zhang, Hua
;
Bao, Jing-jing
;
Chen, Zhen-dong
;
Liu, Xiao-yun
收藏
  |  
浏览/下载:69/0
  |  
提交时间:2021/06/11
metabolism
mass balance
distribution
covalent binding
furmonertinib
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:
Meng, Jian
;
Zhang, Hua
;
Bao, Jing-jing
;
Chen, Zhen-dong
;
Liu, Xiao-yun
收藏
  |  
浏览/下载:72/0
  |  
提交时间:2021/06/11
metabolism
mass balance
distribution
covalent binding
furmonertinib
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers
期刊论文
INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8
作者:
Zhu, Yun-ting
;
Zhang, Yi-fan
;
Jiang, Jin-fang
;
Yang, Yong
;
Guo, Li-xia
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2021/05/24
Alflutinib
Rifampicin
CYP3A4
AST5902
Drug-drug interaction
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo
期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 9
作者:
Dai, Meng-di
;
Wang, Yue-liang
;
Fan, Jun
;
Dai, Yang
;
Ji, Yin-chun
收藏
  |  
浏览/下载:33/0
  |  
提交时间:2021/05/24
receptor tyrosine kinase
FGFR inhibitor
DW14383
antitumor activity
Pharmacokinetics, mass balance, and metabolism of [C-14]vicagrel, a novel irreversible P2Y(12) inhibitor in humans
期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 12
作者:
Zheng, Yuan-dong
;
Zhang, Hua
;
Zhan, Yan
;
Bian, Yi-cong
;
Ma, Sheng
收藏
  |  
浏览/下载:44/0
  |  
提交时间:2021/05/24
vicagrel
[C-14]vicagrel
vicagrel pharmacokinetics
vicagrel metabolism
mass balance
P2Y(12) receptor inhibitor
Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 184, 页码: 15
作者:
Lu, Wenchao
;
Wang, Jun
;
Li, Yong
;
Tao, Hongru
;
Xiong, Huan
收藏
  |  
浏览/下载:94/0
  |  
提交时间:2020/07/01
Hippo pathway
TEAD transcription factor
Covalent inhibitor
Palmitoylation inhibitor
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry
期刊论文
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6
作者:
Liu, Xiaoyun
;
Li, Wei
;
Zhang, Yifan
;
Jian, Yong
;
Zhao, Qianyu
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2020/07/01
LC-MS/MS
Alflutinib
AST2818
Pharmacokinetics
Human plasma
A novel irreversible and selective BTK inhibitor, ameliorates rheumatoid arthritis by dual inhibition of BCR and osteoclastogenic signaling
期刊论文
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 卷号: 49, 页码: 1857-1857
作者:
Liu, Y.
;
Lin, Z.
;
He, S.
;
Zuo, J.
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2020/07/01
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:
Li, Qiao
;
Guan, Xiuwen
;
Chen, Shanshan
;
Yi, Zongbi
;
Lan, Bo
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2020/07/01
©版权所有 ©2017 CSpace - Powered by
CSpace